A new study performed at Oslo University Hospital has validated the usability of Capitainer’s pioneering self-sampling device for the standard panel of biomarkers used for monitoring kidney transplanted patients. Capitainer maintained consistent sampling success and analytical quality, generating reliable results regardless of whether the microsampling was performed by healthcare personnel or the patient.
Medical technology company Capitainer’s patented sampling products are based on patients taking blood samples, themselves or with assistance, using a unique technology for collecting an exact amount of fluid and then allowing it to dry on a sample card. The dried sample can easily in a cost-efficient way be shipped to the laboratory for analysis.
A recent study, published in the British Journal of Clinical Pharmacology, compared the clinical performance of two volumetric microsampling devices for monitoring the standard panel of biomarkers in kidney transplant recipients, including tacrolimus, creatinine, and hemoglobin. New analytical methods were developed and compared to the standard solutions for blood samples taken at hospitals.
The study concludes that both devices tested were technically viable for measuring the biomarkers, although Capitainer’s device exhibited superiority. Capitainer consistently demonstrated high-quality successful sampling events, with analytical results being identically accurate for at-home sampling by patients and sampling in the hospital assisted by a nurse.
The study was performed at Oslo University Hospital, where 25 kidney transplant recipients completed the main study and 12 completed a post hoc validation study.
“The study shows that successful home-testing of these important analyses is possible with Capitainer’s qDBS solution. Not having to visit the healthcare system for traditional sampling is significantly improving the quality of life for patients who have undergone a kidney transplant, where repeated and frequent sampling is an important part of the postoperative process,” says MD Mathias Karlsson, Chief Medical Officer at Capitainer.
“The proof that Capitainer’s solution enables samples to be taken at home with the same quality as if taken by a nurse in the hospital, reinforces our belief and mission that Capitainer’s products have a given place in the fast-growing market for at-home sampling solutions. We firmly believe that Capitainer’s product line is strategically positioned within this expansive landscape,” says Christopher Aulin, CEO of Capitainer.
Read the study: ”Clinical performance of volumetric finger‐prick sampling for the monitoring of tacrolimus, creatinine and hemoglobin in kidney transplant recipients”, Vethe – British Journal of Clinical Pharmacology – Wiley Online Library.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Capitainer AB is a Swedish medtech company founded in 2016. Capitainer develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed unique technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples are market-leading and perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.